Patent Assignment
Reel/Frame 074858/0429
Release of Security Interest in Patents Previously Recorded at Reel/Frame (073213/0302)
Recorded: 2026-02-13
Pages: 27
Assignor
JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Executed: 2026-02-12
Assignee
ALKERMES PHARMA IRELAND LIMITED
900 WINTER STREET, ATTENTION: JOSHUA REED, WALTHAM, MASSACHUSETTS, 02451
Covered Properties
(148)
Monomethylfumarate Prodrug Compositions
Application:
18/652,015 →
Publication:
US US20250057770A1
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Application:
19/210,100 →
Publication:
US US20260001890A1
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Application:
18/780,600 →
Publication:
US US20250127747A1
Sustained Release Aminopyridine Composition
Application:
17/743,258 →
Publication:
US US20220265624A1
Immediate Release Multilayer Tablet
Application:
19/301,647 →
Publication:
US US20250367213A1
Immediate Release Multilayer Tablet
Application:
18/510,590 →
Publication:
US US20240091237A1
Immediate Release Multilayer Tablet
Application:
19/190,529 →
Publication:
US US20250262221A1
Pharmaceutical Compositions Comprising Sorbitan Esters
Application:
18/183,257 →
Publication:
US US20240058327A1
Pharmaceutical Compositions Comprising Sorbitan Esters
Pharmaceutical Compositions Having Improved Storage Stability
Application:
19/187,434 →
Publication:
US US20250312459A1
Aripiprazole Formulations Having Increased Injection Speeds
Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia
Application:
18/543,767 →
Publication:
US US20240245676A1
Aripiprazole Dosing Strategy
Application:
19/050,895 →
Publication:
US US20250248997A1
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Application:
18/948,416 →
Publication:
US US20250214940A1
Aripiprazole Prodrug Composition
Sulfonamide and Sulfinamide Prodrugs of Fumarates and Their Use in Treating Various Diseases
Sulfonamide and Sulfinamide Prodrugs of Fumarates and Their Use in Treating Various Diseases
Polymorphic Forms of Naltrexone
Naltrexone Long Acting Formulations and Methods of Use
Prodrugs of Heteraromatic Compounds
Prodrugs of Heteraromatic Compounds
Morphinan Derivatives for the Treatment of Drug Overdose
Process for Synthesizing Oxidized Lactam Compounds
Process for Synthesizing Oxidized Lactam Compounds
Process for Synthesizing Oxidized Lactam Compounds
Process for Synthesizing Oxidized Lactam Compounds
Process for the Synthesis of Substituted Morphinans
Process for the Synthesis of Substituted Morphinans
Prodrugs of Nh-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives
Methods for Treating Antipsychotic-Induced Weight Gain
Methods for Treating Antipsychotic-Induced Weight Gain
Methods for Treating Antipsychotic-Induced Weight Gain
Methods for Treating Antipsychotic-Induced Weight Gain
Methods for Treating Antipsychotic-Induced Weight Gain
Methods for Treating Antipsychotic-Induced Weight Gain
Methods for Treating Antipsychotic-Induced Weight Gain
Methods for Treating Antipsychotic-Induced Weight Gain
Methods for Treating Antipsychotic-Induced Weight Gain
Composition for Treating Mental Illness
Methods for Treating Antipsychotic-Induced Weight Gain
Prodrugs of Secondary Amine Compounds
Prodrugs of Secondary Amine Compounds
COMPOSITIONS OF BUPRENORPHINE AND µ ANTAGONISTM
COMPOSITIONS OF BUPRENORPHINE AND µ ANTAGONIST
COMPOSITIONS OF BUPRENORPHINE AND µ ANTAGONIST
Compositions of Buprenorphine and µ AntagonistN
Compositions of Buprenorphine and µ AntagonistS
Opioid Agonist Antagonist Combinations
Opioid Agonist Antagonist Combinations
Opioid Agonist Antagonist Combinations
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Patent:
8,669,281 →
Application:
14/032,736 →
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Prodrugs of Fumarates and Their Use in Treating Various Diseases
Novel Naphthylenyl Compounds for Long-Acting Injectable Compositions and Related Methods
Nanoparticulate Meloxicam Formulations
Nanoparticulate Meloxicam Formulations
Nanoparticulate Meloxicam Formulations
Method of Treating Pain in Elderly Patients with Mild Renal Impairment
Methods of Administering Intravenous Meloxicam in a Bolus Dose
Sterilization of Dispersions of Nanoparticulate Active Agents with Gamma Radiation
Injectable Nanoparticulate Olanzapine Formulations
Compositions of Multiple Aripiprazole Prodrugs
Abuse-resistant pharmaceutical compositions
Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions
Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions
Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions
Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions
Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions
Immediate Release Multilayer Tablet
Immediate Release Multilayer Tablet
Immediate Release Multilayer Tablet
Pharmaceutical Compositions Comprising Sorbitan Esters
Pharmaceutical Compositions Comprising Sorbitan Esters
Pharmaceutical Compositions Comprising Sorbitan Esters
Pharmaceutical Compositions Comprising Fatty Acid Esters
Pharmaceutical Compositions Comprising Fatty Glycerol Esters
Pharmaceutical Compositions Comprising Benzyl Alcohol
Pharmaceutical Compositions Having Improved Storage Stability
Pharmaceutical Compositions Having Improved Storage Stability
Pharmaceutical Compositions Having Improved Storage Stability
Pharmaceutical Compositions Having Improved Storage Stability
Pharmaceutical Compositions Having Improved Storage Stability
Pharmaceutical Compositions Having Improved Storage Stability
Pharmaceutical Compositions Having Improved Storage Stability
Morphan and Morphinan Analogues, and Methods of Use
Morphan and Morphinan Analogues, and Methods of Use
Morphan and Morphinan Analogues, and Methods of Use
Morphan And Morphinan Analogues, And Methods Of Use
Morphan And Morphinan Analogues, And Methods Of Use
Methods for Treating Depressive Symptoms
Methods for Treating Depressive Symptoms
Methods for Treating Depressive Symptoms
Methods for Treating Depressive Symptoms
Aripiprazole Formulations Having Increased Injection Speeds
Aripiprazole Formulations Having Increased Injection Speeds
Aripiprazole Formulations Having Increased Injection Speeds
Aripiprazole Formulations Having Increased Injection Speeds
Aripiprazole Formulations Having Increased Injection Speeds
Aripiprazole Formulations Having Increased Injection Speeds
Aripiprazole Formulations Having Increased Injection Speeds
Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia
Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia
Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia
Crystallization Process of Aripiprazole Derivatives in Extended Release Formulations for Treatment of Schizophrenia
Aripiprazole Dosing Strategy
Aripiprazole Dosing Strategy
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
Prodrugs of Nh-Acidic Compounds
Prodrugs of Nh-Acidic Compounds
Prodrugs of Nh-Acidic Compounds
Prodrugs of NH-Acidic Compounds
Prodrugs of Nh-Acidic Compounds
Aripiprazole Prodrug Composition
Aripiprazole Prodrug Composition
Aripiprazole Prodrug Composition
Aripiprazole Prodrug Compositions
Nanoparticulate Compositions Having Lysozyme as a Surface Stabilizer
Polymer-Based Sustained Release Device
Polymer-Based Sustained Release Device
Nanoparticulate Megestrol Formulations
Prodrugs of Nh-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives
Polymer-Based Sustained Release Device
Polymer-Based Sustained Release Device
Poly(Lactide-Co-Glycolide) Based Sustained Release Microcapsules Comprising a Polypeptide and a Sugar
Polymer-Based Sustained Release Device
COMPOSITIONS OF BUPRENORPHINE AND µ ANTAGONIST1
COMPOSITIONS OF BUPRENORPHINE AND µ ANTAGONIST
Multi-Api Loading Prodrugs
Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions
Sustained Release Aminopyridine Composition
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Merger
Oct 31, 2007
From: ALKERMES CONTROLLED THERAPEUTICS, II
To: ALKERMES, INC.
Reel/Frame 020035/0827 →
Assignment of Assignor's Interest
Mar 18, 2011
From: BLUMBERG, LAURA COOK; ALMARSSON, ORN
To: ALKERMES, INC.
Reel/Frame 025980/0425 →
Patent Security Agreement (Second Lien)
Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →
Patent Security Agreement (First Lien)
Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0186 →
Assignment of Assignor's Interest
Jun 27, 2012
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 028450/0795 →
Release by Secured Party (Second Lien)
Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
Assignment of Assignor's Interest
Apr 13, 2015
From: WYNN, THOMAS ANDREW; HENCKEN, CHRISTOPHER P.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 035395/0205 →
Assignment of Assignor's Interest
Jun 1, 2015
From: WYNN, THOMAS ANDREW; HENCKEN, CHRISTOPHER P.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 035754/0719 →
Assignment of Assignor's Interest
Oct 16, 2015
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 036809/0447 →
Security Interest
Apr 4, 2017
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 041846/0029 →
Security Interest
Feb 7, 2018
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 044857/0371 →
Security Interest
Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →
Assignment of Assignor's Interest
Apr 11, 2022
From: CRESSWELL, PHILIP; HICKEY, MAGALI; PERKIN, KRISTOPHER; SMITH, GREG
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 059563/0274 →
Security Agreement
Jul 17, 2023
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 064286/0821 →
Assignment of Assignor's Interest
Nov 22, 2023
From: CHIARELLA, RENATO A.; GUZMAN, HECTOR; HURLEY, PAUL; MANSER, DAVID
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 065648/0397 →
Assignment of Assignor's Interest
Mar 11, 2024
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 066715/0987 →
Assignment of Assignor's Interest
Mar 11, 2024
From: MORALES, WILFREDO; ZEIDAN, TAREK A.; PERRY, JASON M.; WRIGHT, STEVEN G.
To: ALKERMES, INC.
Reel/Frame 066715/0225 →
Assignment of Assignor's Interest
Mar 12, 2024
From: PERRY, JASON M.; DEAVER, DANIEL R.; HICKEY, MAGALI B.; REMENAR, JULIUS F.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 066737/0731 →
Release of Patent Security Agreement (First Lien)
Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0548 →
Release of Patent Security Agreements
Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0701 →
Assignment of Assignor's Interest
Feb 18, 2025
From: REMENAR, JULIUS F.; BLUMBERG, LAURA COOK; ZEIDAN, TAREK A.
To: ALKERMES, INC.
Reel/Frame 070247/0043 →
Assignment of Assignor's Interest
Feb 18, 2025
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 070247/0107 →
Assignment of Assignor's Interest
Feb 24, 2025
From: PERRY, JASON M.; DEAVER, DANIEL R.; HICKEY, MAGALI B.; REMENAR, JULIUS F.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 070301/0553 →
Assignment of Assignor's Interest
May 12, 2025
From: VON MOLTKE, LISA L.; WEIDEN, PETER J.; HARD, MARJIE L.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 071088/0952 →
Security Interest
Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →